An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Inclusion Criteria:

• Participants who have provided informed consent prior to initiation of anystudy-specific activities/procedures.

• Participants who have completed the parent study EOS visit while still on assignedinvestigational product.

Exclusion Criteria:

• Participants who for any reason permanently discontinued or have interrupted theinvestigational product for continuous 6 months at EOS during the parent study.

• Participants who have a history or evidence of any clinically significant disorder,condition, or disease that in the opinion of the investigator or Novartis physician (if consulted), would put the participant at risk or interfere with the studyparticipation, including, but not restricted to conditions outlined in Table 6-3 andTable 6-5.

• Participants are receiving another investigational drug or device before theopen-label treatment period.

• Participants have a known sensitivity to the study drug and are deemed as unsuitedfor the study by the Investigator at Screening visit.

Other protocol-defined inclusion/exclusion criteria may apply.